The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring
- Creators
- Batool, Syeda Maheen
- Yekula, Anudeep
- Khanna, Prerna
- Hsia, Tiffaney
- Gamblin, Austin S.
- Ekanayake, Emil
- Escobedo, Ana K.
- You, Dong Gil
- Castro, Cesar M.
- Im, Hyungsoon
- Kilic, Tugba
- Garlin, Michelle Andrea
- Skog, Johan
- Dinulescu, Daniela M.
- Dudley, Jonathan
- Agrawal, Nishant
- Cheng, Jordan
- Abtin, Fereidoun
- Aberle, Denise R.
- Chia, David
- Elashoff, David
- Grognan, Tristan
- Krysan, Kostyantyn
- Oh, Scott S.
- Strom, Charles
- Tu, Michael
- Wei, Fang
- Xian, Rena R.
- Skates, Steven J.
- Zhang, David Y.
- Trinh, Thi
- Watson, Mark
- Aft, Rebecca
- Rawal, Siddarth
- Agarwal, Ashutosh
- Kesmodel, Susan B.
- Yang, Changhuei1
- Shen, Cheng
- Hochberg, Fred H.
- Wong, David T.W.
- Patel, Abhijit A.
- Papadopoulos, Nickolas
- Bettegowda, Chetan
- Cote, Richard J.
- Srivastava, Sudhir
- Lee, Hakho
- Carter, Bob S.
- Balaj, Leonora
Abstract
The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.
Copyright and License
© 2023 The Authors. Under a Creative Commons license Attribution-NonCommercial-NoDerivs 4.0 International.
Acknowledgement
This work is supported by the Division of Cancer Prevention, National Cancer Institute grants U01 CA230697 (B.S.C., L.B.), P01 CA069246 (B.S.C., L.B.), R01CA239078 (B.S.C., H.L.), CA237500 (B.S.C., L.B.), U01CA233360 (H.L., C.M.C., J.S.), and R01CA229777 (H.L., J.S.).
Conflict of Interest
The authors declare no competing interests.
Files
Name | Size | Download all |
---|---|---|
md5:171e7e730cfaa39af133570735a88ca4
|
2.7 MB | Preview Download |
md5:9ac7a5c4107fd7ca9cec38feb3e3d20c
|
295.8 kB | Preview Download |
Additional details
- PMCID
- PMC10591039
- National Institutes of Health
- CA237500
- National Institutes of Health
- R01CA239078
- National Institutes of Health
- P01 CA069246
- National Institutes of Health
- R01CA229777
- National Institutes of Health
- U01 CA230697
- National Institutes of Health
- U01CA233360
- National Institutes of Health